# Kypha

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kypha

- Industry: Medical Devices & Equipment
- Headquarters: St. Louis, US
- Website: www.kypha.net
- Total disclosed funding: $4M
- Latest round: Series A (Dec 20, 2018)
- Investors on record: 1

## About

Kypha Inc. is a biotechnology company specializing in advanced immune monitoring solutions that enhance therapeutic development and clinical care for patients with immune-related conditions.Founded in 2009, Kypha Inc. is based in St. Louis, US. The company focuses on providing advanced immune monitoring solutions and has established itself as a player in this niche market. The founders of Kypha, Chad Stiening and Paul Olson, have backgrounds that contribute to the company's capabilities. In December 2018, Kypha raised USD 4 million in Series A funding led by Arsenal Capital Partners, with the total amount raised also being USD 4 million. The company has successfully completed 14 deals, showcasing its active participation in the market.Kypha specializes in advanced immune monitoring solutions, providing products and services that enhance therapeutic development and clinical care for patients with immune-related conditions. Their core offerings, RapiPlex™ and Comp ACT®, allow simultaneous, quantitative multiplex analysis of up to 24 biological markers from various sample types. These systems deliver real-time, precise information about complement proteins, cytokines, and chemokines, enabling healthcare providers to make informed treatment decisions. Kypha also offers assay development and manufacturing services in compliance with ISO13485, GMP, and CLSI guidelines, primarily serving clinical laboratories and research institutions across North America and Europe.Kypha generates revenue through direct sales of its proprietary diagnostic systems and services, which cater to the bioanalytical and companion diagnostic needs of its clients. Their revenue model includes one-time purchases of testing systems, assay kits, and ongoing contracts for support and development services, enabling B2B interactions with clinical labs and healthcare providers. The flagship products RapiPlex™ and Comp ACT® command premium pricing due to their advanced capabilities, with revenue expected from strategic contracts and direct sales addressing specific client needs in the healthcare sector.Kypha plans to leverage the USD 4 million raised in Series A funding from December 2018 to support the development of new products, expand into new markets, and enhance its service offerings. The company is exploring opportunities for launching additional immune monitoring solutions aimed at addressing unmet clinical needs. Targeted markets for geographic expansion include Europe and potentially other regions by 2024. The recent funding will enable Kypha to accelerate its product development timeline and establish partnerships with additional clinical laboratories and research institutions.

## Funding rounds

- Series A, Dec 20, 2018, $4M — Arsenal Capital Partners

## Investors

- Arsenal Capital Partners (https://capitalatlas.ai/funds/arsenal-capital-partners) — Series A